Ryvu Therapeutics S.A. (RVU.WA)
PLN 36.5
(-3.95%)
PLN 36.5
(-3.95%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 403.2 Million PLN | -15.11% |
| 2022 | 474.97 Million PLN | 107.58% |
| 2021 | 228.81 Million PLN | -22.6% |
| 2020 | 295.64 Million PLN | 61.65% |
| 2019 | 182.89 Million PLN | -28.47% |
| 2018 | 255.69 Million PLN | 146.88% |
| 2017 | 103.57 Million PLN | 16.22% |
| 2016 | 89.12 Million PLN | 36.6% |
| 2015 | 65.24 Million PLN | 143.41% |
| 2014 | 26.8 Million PLN | 49.09% |
| 2013 | 17.97 Million PLN | 17.13% |
| 2012 | 15.34 Million PLN | -12.31% |
| 2011 | 17.5 Million PLN | 70.44% |
| 2010 | 10.26 Million PLN | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 404.83 Million PLN | 0.4% |
| 2024 Q2 | 406.64 Million PLN | 0.45% |
| 2023 Q2 | 425.25 Million PLN | -5.33% |
| 2023 Q1 | 449.18 Million PLN | -5.43% |
| 2023 FY | 403.2 Million PLN | -15.11% |
| 2023 Q4 | 403.2 Million PLN | -8.33% |
| 2023 Q3 | 439.82 Million PLN | 3.43% |
| 2022 Q3 | 169.83 Million PLN | -5.32% |
| 2022 Q1 | 201.4 Million PLN | -11.98% |
| 2022 Q2 | 179.37 Million PLN | -10.94% |
| 2022 FY | 474.97 Million PLN | 107.58% |
| 2022 Q4 | 474.97 Million PLN | 179.67% |
| 2021 Q2 | 253.34 Million PLN | -10.21% |
| 2021 Q1 | 282.15 Million PLN | -4.56% |
| 2021 Q3 | 233.89 Million PLN | -7.68% |
| 2021 Q4 | 228.81 Million PLN | -2.17% |
| 2021 FY | 228.81 Million PLN | -22.6% |
| 2020 Q4 | 295.64 Million PLN | 0.27% |
| 2020 Q1 | 178.26 Million PLN | -2.53% |
| 2020 FY | 295.64 Million PLN | 61.65% |
| 2020 Q2 | 167.83 Million PLN | -5.85% |
| 2020 Q3 | 294.83 Million PLN | 75.67% |
| 2019 Q2 | 278.77 Million PLN | 5.93% |
| 2019 Q4 | 182.89 Million PLN | -32.39% |
| 2019 Q1 | 263.17 Million PLN | 2.92% |
| 2019 FY | 182.89 Million PLN | -28.47% |
| 2019 Q3 | 270.51 Million PLN | -2.96% |
| 2018 Q4 | 255.69 Million PLN | -2.08% |
| 2018 FY | 255.69 Million PLN | 146.88% |
| 2018 Q2 | 260.19 Million PLN | 3.36% |
| 2018 Q1 | 251.72 Million PLN | 143.04% |
| 2018 Q3 | 261.12 Million PLN | 0.36% |
| 2017 Q3 | 103.31 Million PLN | 2.39% |
| 2017 Q4 | 103.57 Million PLN | 0.25% |
| 2017 FY | 103.57 Million PLN | 16.22% |
| 2017 Q2 | 100.9 Million PLN | 5.78% |
| 2017 Q1 | 95.39 Million PLN | 7.03% |
| 2016 Q1 | 64.86 Million PLN | -0.57% |
| 2016 FY | 89.12 Million PLN | 36.6% |
| 2016 Q4 | 89.12 Million PLN | 21.02% |
| 2016 Q3 | 73.64 Million PLN | 9.9% |
| 2016 Q2 | 67 Million PLN | 3.3% |
| 2015 Q4 | 65.24 Million PLN | 10.81% |
| 2015 Q1 | 51.71 Million PLN | 92.95% |
| 2015 Q2 | 59.13 Million PLN | 14.34% |
| 2015 Q3 | 58.87 Million PLN | -0.42% |
| 2015 FY | 65.24 Million PLN | 143.41% |
| 2014 Q4 | 26.8 Million PLN | 9.34% |
| 2014 FY | 26.8 Million PLN | 49.09% |
| 2014 Q1 | 19.52 Million PLN | 8.58% |
| 2014 Q2 | 22.56 Million PLN | 15.57% |
| 2014 Q3 | 24.51 Million PLN | 8.66% |
| 2013 Q3 | 17.09 Million PLN | 0.0% |
| 2013 Q4 | 17.97 Million PLN | 5.13% |
| 2013 FY | 17.97 Million PLN | 17.13% |
| 2013 Q2 | - PLN | -100.0% |
| 2013 Q1 | 5.57 Million PLN | -63.67% |
| 2012 Q4 | 15.34 Million PLN | 0.0% |
| 2012 FY | 15.34 Million PLN | -12.31% |
| 2011 FY | 17.5 Million PLN | 70.44% |
| 2010 FY | 10.26 Million PLN | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioceltix S.A. | 12.73 Million PLN | -3066.02% |
| BIOTON S.A. | 822.22 Million PLN | 50.962% |
| Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | -314.416% |
| Mabion S.A. | 208.25 Million PLN | -93.611% |
| Molecure S.A. | 168.57 Million PLN | -139.179% |
| NanoGroup S.A. | 8.63 Million PLN | -4571.239% |
| Pharmena S.A. | 24.13 Million PLN | -1570.819% |
| Poltreg S.A. | 127.09 Million PLN | -217.237% |
| Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -1673.252% |
| Synthaverse S.A. | 265.9 Million PLN | -51.635% |
| Urteste S.A. | 29.59 Million PLN | -1262.261% |